Global Gene Therapy Market Size, Share, Opportunities, COVID 19 Impact, And Trends By Technique (Gene Augmentation, Gene Inhibition, Killing Of Specific Cells), By Vector Type (Viral Vectors, Non-Viral Vectors), By Indication (Genetic Disorders, Cardiovascular, Oncology, Others) And By Geography - Forecasts From 2019 To 2024

Published:  May 2021 Report Code: KSI061611924 Pages: 127

The gene therapy market was valued at US$3.425 billion in 2018 and is anticipated to grow at a CAGR of 16.92% to reach a market size of US$8.748 billion by 2024. Gene Therapy is to insert genes instead of drugs in order to treat a disease or a disorder. It is done either:

• to replace an unhealthy gene with a healthy copy of a gene

• to inactivate or knock out a gene not functioning properly

• to introduce a new gene into a body in order to fight disease.

Gene Therapy has a huge potential in curing otherwise deadly diseases. It is used in treating diseases like cancer, diabetes, inherited blindness, HIV, etc. Hence, at present and in the future cancer gene therapy will hold a significant market share due to advancements in cancer research and treatment. Although gene therapy medicines are being commercialized major revenue is still being gained by clinical research, this is because it involves the use of gene therapy on human beings, therefore, efforts are made to focus more on clinical research before being market-ready. Hence, growing clinical trials worldwide are further driving the market growth in the forecast period and in the coming years.

Geographically, North America is expected to hold a significant market share owing to the prevalence of cancer in addition to the highest health expenditure of the United States among all the developed regions of the world.

The Gene Therapy Market – Forecasts from 2019 to 2024 is an exhaustive study that aims to present the key market trends through various chapters focusing on different aspects of the market. The study provides a detailed market overview through the market dynamics sections which detail key markets, drivers, restraints, and opportunities in the current market. The report analyzes key opportunity regional markets, and the current technology penetration through lifecycle analysis. The report also analyzes the market through comprehensive market segmentation by type, technique, vector type, indication, and geography.

The gene therapy market has been segmented based on type, technique, vector type, indication, and geography. Based on type, the market has been segmented into somatic gene therapy and germline gene therapy. On the basis of technique, the market has been segmented into gene augmentation, gene inhibition, and the killing of specific cells. Based on vector type, the market is segmented into viral vectors and non-viral vectors. By indication, the market is categorized as rare diseases, cardiovascular, oncology, and others.  

Regional analysis has been provided with detailed analysis and forecast for the period 2018 to 2024. The global market has been broken down into North America, South America, Europe, Middle East and Africa (MEA), and the Asia Pacific regions. The report also analyzes 15 major countries across these regions with thorough analysis and forecast along with prevailing market trends and opportunities which each of these countries present for the manufacturers.

Major players in the gene therapy market have been covered along with their relative competitive position and strategies. The report also mentions recent deals and investments of different market players over the last year. The company profiles section details the business overview, financial performance for the past three years, key products and services being offered along with the recent developments of these important players in the gene therapy market.

Global Gene Therapy Market Scope:

Report Metric Details
 Market size value in 2018  US$3.425 billion
 Market size value in 2024  US$8.748 billion
 Growth Rate  CAGR of 16.92% from 2018 to 2024
 Base year  2018
 Forecast period  2019–2024
 Forecast Unit (Value)  USD Billion
 Segments covered  Type, Technique, Vector Type, Indication, And Geography
 Regions covered  North America, South America, Europe, Middle East and Africa, Asia Pacific
 Companies covered AveXis, Inc, Pfizer Inc., MeiraGTx Limited, Errant Gene Therapeutics, American Gene Technologies Inc., IVERIC bio, Inc., Lysogene, AVROBIO, Inc., Adverum Biotechnologies, Spark Therapeutics, Inc.
 Customization scope  Free report customization with purchase

Segmentation:

  • By Type
    • Somatic Gene Therapy
    • Germline Gene Therapy
    •  
  • By Technique
    • Gene Augmentation
    • Gene Inhibition
    • Killing of specific cells
    •  
  • By Vector Type
    • Viral Vector
    • Non-Viral Vector
    •  
  • By Indication
    • Rare diseases
    • Cardiovascular
    • Oncology
    • Others
    •  
  • By Geography
    • North America
      • USA
      • Canada
      • Mexico
    • South America
      • Brazil
      • Argentina
      • Others
    • Europe
      • United Kingdom
      • Germany
      • France
      • Spain
      • Others
    • Middle East and Africa
      • Saudi Arabia
      • Israel
      • Others
    • Asia Pacific
      • China
      • Japan
      • India
      • South Korea
      • Others

Frequently Asked Questions (FAQs)

Q1. What will be the gene therapy market size by 2024?
A1. The gene therapy market is anticipated to reach a total market size of US$8.748 billion by 2024.
 
Q2. What is the size of the global gene therapy market?
A2. Gene Therapy market was valued at US$3.425 billion in 2018.
 
Q3. What are the growth prospects for the gene therapy market?
A3. The global gene therapy market is anticipated to grow at a CAGR of 16.92% during the forecast period.
 
Q4. Which region holds the largest market share in the gene therapy market?
A4. Geographically, North America is expected to hold a significant share in the gene therapy market owing to the prevalence of cancer in addition to the highest health expenditure of the United States among all the developed regions of the world.
 
Q5. How is the global gene therapy market segmented?
A5. The gene therapy market has been segmented based on type, technique, vector type, indication, and geography.
1. INTRODUCTION
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Currency
1.5. Assumptions
1.6. Base, And Forecast Years Timeline
 
2. RESEARCH METHODOLOGY
2.1. Research Design
2.2. Secondary Sources
 
3. EXECUTIVE SUMMARY
 
4. MARKET DYNAMICS
4.1.  Market Segmentation
4.2. Market Drivers
4.3. Market Restraints
4.4. Market Opportunities
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Competitive Rivalry in the Industry
4.6. Life Cycle Analysis - Regional Snapshot
4.7. Market Attractiveness
 
5. GENE THERAPY MARKET BY TYPE
5.1. Somatic Gene Therapy
5.2. Germline Gene Therapy
 
6. GENE THERAPY MARKET BY TECHNIQUE
6.1. Gene Augmentation
6.2. Gene Inhibition
6.3. Killing of specific cells
 
7. GENE THERAPY MARKET BY VECTOR TYPE
7.1. Viral Vectors
7.2. Non-Viral Vectors
 
8. GENE THERAPY MARKET BY INDICATION
8.1. Rare diseases
8.2. Cardiovascular
8.3. Oncology
8.4. Others
 
9. GENE THERAPY  MARKET BY GEOGRAPHY
9.1. North America
9.1.1. USA
9.1.2. Canada
9.1.3. Mexico
9.2. South America
9.2.1. Brazil
9.2.2. Argentina
9.2.3. Others
9.3. Europe 
9.3.1. Germany
9.3.2. United Kingdom
9.3.3. France 
9.3.4. Spain
9.3.5. Others
9.4. Middle East and Africa
9.4.1. Saudi Arabia
9.4.2. Israel
9.4.3. Others
9.5. Asia Pacific
9.5.1. China
9.5.2. Japan
9.5.3. India
9.5.4. South Korea
9.5.5. Others
 
10. COMPETITIVE INTELLIGENCE
10.1. Competitive Benchmarking and Analysis
10.2. Strategies of Key Players
10.3. Recent Investments and Deals 
 
11. COMPANY PROFILES
11.1. AveXis, Inc
11.2. Pfizer Inc.
11.3. MeiraGTx Limited
11.4. Errant Gene Therapeutics
11.5. American Gene Technologies Inc.
11.6. IVERIC bio, Inc.
11.7. Lysogene
11.8. AVROBIO, Inc. 
11.9. Adverum Biotechnologies
11.10. Spark Therapeutics, Inc.

AveXis, Inc

Pfizer Inc.

MeiraGTx Limited

Errant Gene Therapeutics

American Gene Technologies Inc.

IVERIC bio, Inc.

Lysogene

AVROBIO, Inc.

Adverum Biotechnologies

Spark Therapeutics, Inc.

Pricing

Explore Custom Options available with this study:

  •  Request customization
  •  Buy sections of the study
  •  Buy country specific report
  •  Request excel, Historical data
  •  Subscription inquiry
  •  Request special pricing

Our Value Proposition

Analyst Support

All our studies come with 2 months of analyst support.


Confidentiality

We are in compliance with the global privacy laws.

Connect With Us